Cécile Matthews and Bhavesh Patel were quoted in Pink Sheet regarding their analysis entitled “How do rare disease patient numbers in Germany affect prices for non-oncology orphan drugs?” In Pink Sheet, Matthews and Patel discuss factors to consider when agreeing on a price including benefit ratings, patient populations, and budget impact.
MFN is rewriting the launch planning playbook: Commercial and market access strategies must integrate to succeed
MFN-related uncertainty is reshaping pharmaceutical launch planning by making pricing, sequencing, and forecasting decisions more interconnected and...